CD19-targeting CAR T cell therapy in five patients with systemic sclerosis unsuitable for autologous stem cell transplantation

Ann‐Christin Pecher(STZ eyetrial), Jörg Henes(University of Tübingen), Luca Hensen(University Children's Hospital Tübingen), Rebekka Schairer(University Children's Hospital Tübingen), Claudia Lengerke(University Children's Hospital Tübingen), Reinhild Klein(University Children's Hospital Tübingen), Wolfgang Bethge(University of Tübingen)

EULAR Rheumatology Open

April 1, 2025

10.1016/j.ero.2025.03.005

Cited by 10

Related Papers

Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation

|Blood|2010|430

Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies

|JAMA|2011|320

Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)

|Journal of Clinical Oncology|2017|248

CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome

|JAMA|2023|234

Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation

|Journal of Clinical Oncology|2013|212